Concepts (191)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Small Molecule Libraries | 12 | 2025 | 138 | 3.800 |
Why?
|
| Drug Discovery | 7 | 2024 | 179 | 1.660 |
Why?
|
| Drug Design | 4 | 2021 | 168 | 1.630 |
Why?
|
| Proto-Oncogene Proteins c-myc | 3 | 2025 | 218 | 1.440 |
Why?
|
| DNA | 8 | 2024 | 1684 | 1.400 |
Why?
|
| Piperazines | 2 | 2022 | 256 | 1.310 |
Why?
|
| Protease Inhibitors | 2 | 2022 | 100 | 0.880 |
Why?
|
| Molecular Structure | 9 | 2024 | 318 | 0.860 |
Why?
|
| Proteolysis | 1 | 2025 | 198 | 0.860 |
Why?
|
| Pyridines | 2 | 2021 | 251 | 0.840 |
Why?
|
| Diamines | 1 | 2022 | 8 | 0.770 |
Why?
|
| Alkenes | 2 | 2013 | 7 | 0.770 |
Why?
|
| Ubiquitin-Protein Ligases | 2 | 2025 | 393 | 0.760 |
Why?
|
| Stereoisomerism | 7 | 2024 | 119 | 0.720 |
Why?
|
| Tudor Domain | 1 | 2021 | 5 | 0.710 |
Why?
|
| CCAAT-Enhancer-Binding Proteins | 1 | 2021 | 49 | 0.700 |
Why?
|
| Chemistry Techniques, Synthetic | 1 | 2020 | 7 | 0.700 |
Why?
|
| Fluorenes | 1 | 2020 | 8 | 0.690 |
Why?
|
| Molecular Probes | 1 | 2020 | 31 | 0.680 |
Why?
|
| Molecular Biology | 1 | 2020 | 80 | 0.660 |
Why?
|
| Peptides | 2 | 2020 | 864 | 0.650 |
Why?
|
| Staining and Labeling | 1 | 2020 | 187 | 0.640 |
Why?
|
| Contraceptive Agents, Male | 3 | 2024 | 35 | 0.570 |
Why?
|
| Antineoplastic Agents | 2 | 2025 | 1853 | 0.560 |
Why?
|
| Protein Kinase Inhibitors | 4 | 2024 | 609 | 0.510 |
Why?
|
| Macrocyclic Compounds | 2 | 2011 | 12 | 0.450 |
Why?
|
| Cytochrome P-450 CYP3A | 2 | 2024 | 60 | 0.410 |
Why?
|
| Structure-Activity Relationship | 4 | 2024 | 610 | 0.410 |
Why?
|
| Siloxanes | 1 | 2013 | 2 | 0.410 |
Why?
|
| Hydrocarbons, Halogenated | 1 | 2013 | 5 | 0.410 |
Why?
|
| Triazoles | 3 | 2021 | 142 | 0.390 |
Why?
|
| Molecular Conformation | 3 | 2021 | 112 | 0.370 |
Why?
|
| Luciferases | 3 | 2022 | 139 | 0.370 |
Why?
|
| Aza Compounds | 1 | 2011 | 15 | 0.370 |
Why?
|
| Silanes | 1 | 2011 | 1 | 0.360 |
Why?
|
| Ketones | 1 | 2011 | 29 | 0.360 |
Why?
|
| Hydrocarbons, Aromatic | 1 | 2011 | 5 | 0.360 |
Why?
|
| Azepines | 2 | 2021 | 65 | 0.340 |
Why?
|
| Nuclear Proteins | 3 | 2022 | 1351 | 0.340 |
Why?
|
| Biological Assay | 2 | 2022 | 112 | 0.330 |
Why?
|
| Ligands | 5 | 2022 | 571 | 0.320 |
Why?
|
| Catalysis | 5 | 2020 | 139 | 0.310 |
Why?
|
| Combinatorial Chemistry Techniques | 3 | 2021 | 15 | 0.300 |
Why?
|
| Signal Transduction | 6 | 2024 | 4936 | 0.290 |
Why?
|
| Transcription Factors | 3 | 2022 | 2734 | 0.250 |
Why?
|
| Esters | 2 | 2024 | 34 | 0.250 |
Why?
|
| Databases, Factual | 1 | 2011 | 1258 | 0.250 |
Why?
|
| Hydrocarbons, Chlorinated | 1 | 2005 | 15 | 0.240 |
Why?
|
| Lithium | 1 | 2005 | 71 | 0.240 |
Why?
|
| Pyridones | 1 | 2005 | 130 | 0.230 |
Why?
|
| Activin Receptors, Type I | 1 | 2024 | 36 | 0.220 |
Why?
|
| Ubiquitination | 1 | 2025 | 186 | 0.220 |
Why?
|
| Neoplasms | 1 | 2019 | 3034 | 0.220 |
Why?
|
| Microsomes, Liver | 2 | 2023 | 100 | 0.220 |
Why?
|
| Morpholines | 1 | 2024 | 64 | 0.210 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2025 | 278 | 0.210 |
Why?
|
| Contraception | 1 | 2024 | 62 | 0.210 |
Why?
|
| Protein Binding | 4 | 2022 | 1860 | 0.210 |
Why?
|
| Enzyme Activation | 2 | 2022 | 651 | 0.210 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2023 | 307 | 0.210 |
Why?
|
| Neurogenesis | 2 | 2022 | 223 | 0.200 |
Why?
|
| Crystallography, X-Ray | 2 | 2021 | 393 | 0.200 |
Why?
|
| Serotonin and Noradrenaline Reuptake Inhibitors | 1 | 2022 | 13 | 0.200 |
Why?
|
| Cell Line, Tumor | 4 | 2025 | 3799 | 0.200 |
Why?
|
| Cosmic Radiation | 1 | 2022 | 14 | 0.190 |
Why?
|
| Acetic Acid | 1 | 2022 | 18 | 0.190 |
Why?
|
| Gold | 1 | 2022 | 57 | 0.190 |
Why?
|
| Oleic Acid | 1 | 2022 | 19 | 0.190 |
Why?
|
| Radiation Protection | 1 | 2022 | 57 | 0.190 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2023 | 125 | 0.190 |
Why?
|
| Radiation Exposure | 1 | 2022 | 49 | 0.180 |
Why?
|
| Astronauts | 1 | 2022 | 76 | 0.180 |
Why?
|
| Humans | 24 | 2025 | 134143 | 0.180 |
Why?
|
| Binding Sites | 2 | 2021 | 1386 | 0.170 |
Why?
|
| Radiation Injuries | 1 | 2022 | 166 | 0.170 |
Why?
|
| Solutions | 1 | 2020 | 67 | 0.170 |
Why?
|
| Spliceosomes | 1 | 2021 | 57 | 0.170 |
Why?
|
| Genetic Engineering | 1 | 2021 | 164 | 0.170 |
Why?
|
| Histone Code | 1 | 2021 | 53 | 0.170 |
Why?
|
| Oxygen | 1 | 2024 | 580 | 0.170 |
Why?
|
| Oligopeptides | 1 | 2020 | 121 | 0.160 |
Why?
|
| Cyclization | 3 | 2020 | 17 | 0.160 |
Why?
|
| Immunity | 1 | 2021 | 184 | 0.160 |
Why?
|
| Luminescent Measurements | 1 | 2019 | 60 | 0.160 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2022 | 317 | 0.160 |
Why?
|
| Hippocampus | 2 | 2022 | 864 | 0.160 |
Why?
|
| Animals | 13 | 2024 | 36518 | 0.160 |
Why?
|
| Models, Molecular | 2 | 2021 | 1147 | 0.160 |
Why?
|
| Immunologic Factors | 1 | 2020 | 186 | 0.150 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2022 | 396 | 0.150 |
Why?
|
| Space Flight | 1 | 2022 | 170 | 0.150 |
Why?
|
| Virus Replication | 1 | 2021 | 636 | 0.140 |
Why?
|
| Escherichia coli | 2 | 2021 | 1030 | 0.140 |
Why?
|
| Drosophila melanogaster | 1 | 2023 | 845 | 0.140 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2021 | 1735 | 0.140 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2019 | 189 | 0.140 |
Why?
|
| Enzyme Inhibitors | 1 | 2020 | 608 | 0.140 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2021 | 277 | 0.140 |
Why?
|
| Depressive Disorder, Major | 1 | 2022 | 473 | 0.130 |
Why?
|
| Histones | 1 | 2021 | 572 | 0.130 |
Why?
|
| Cell Cycle Proteins | 1 | 2021 | 709 | 0.130 |
Why?
|
| Peptide Fragments | 1 | 2021 | 832 | 0.130 |
Why?
|
| Mice | 10 | 2024 | 19043 | 0.130 |
Why?
|
| Antiviral Agents | 1 | 2022 | 824 | 0.130 |
Why?
|
| Carcinogenesis | 1 | 2019 | 363 | 0.130 |
Why?
|
| Cells, Cultured | 1 | 2021 | 3180 | 0.120 |
Why?
|
| Promoter Regions, Genetic | 4 | 2022 | 1434 | 0.120 |
Why?
|
| Metabolomics | 3 | 2023 | 470 | 0.110 |
Why?
|
| Carcinoma, Ductal | 1 | 2013 | 9 | 0.110 |
Why?
|
| Substrate Specificity | 2 | 2011 | 315 | 0.110 |
Why?
|
| Chemistry, Organic | 1 | 2013 | 7 | 0.100 |
Why?
|
| Chromatography, Liquid | 2 | 2023 | 245 | 0.090 |
Why?
|
| Palladium | 1 | 2011 | 15 | 0.090 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2013 | 168 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2023 | 3867 | 0.090 |
Why?
|
| Biological Products | 2 | 2010 | 138 | 0.090 |
Why?
|
| Carbamates | 1 | 2011 | 68 | 0.090 |
Why?
|
| Gene Library | 2 | 2023 | 225 | 0.090 |
Why?
|
| Aldehydes | 1 | 2010 | 31 | 0.090 |
Why?
|
| Tandem Mass Spectrometry | 2 | 2023 | 294 | 0.080 |
Why?
|
| Testis | 2 | 2024 | 433 | 0.080 |
Why?
|
| Homeodomain Proteins | 1 | 2013 | 589 | 0.080 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2010 | 91 | 0.080 |
Why?
|
| Amino Acids | 2 | 2024 | 688 | 0.080 |
Why?
|
| Systems Biology | 1 | 2010 | 63 | 0.080 |
Why?
|
| Histone Deacetylases | 1 | 2010 | 125 | 0.080 |
Why?
|
| Ruthenium | 1 | 2009 | 5 | 0.080 |
Why?
|
| Trans-Activators | 1 | 2013 | 838 | 0.080 |
Why?
|
| Alkynes | 1 | 2009 | 27 | 0.080 |
Why?
|
| Disease | 1 | 2010 | 133 | 0.080 |
Why?
|
| Genes, Reporter | 2 | 2020 | 399 | 0.080 |
Why?
|
| Plasmids | 2 | 2020 | 531 | 0.070 |
Why?
|
| High-Throughput Screening Assays | 2 | 2021 | 110 | 0.070 |
Why?
|
| Recombinant Proteins | 2 | 2021 | 1436 | 0.070 |
Why?
|
| Genetic Vectors | 2 | 2021 | 967 | 0.060 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2013 | 2137 | 0.060 |
Why?
|
| Activin Receptors, Type II | 1 | 2024 | 33 | 0.060 |
Why?
|
| Proteins | 1 | 2010 | 1100 | 0.060 |
Why?
|
| Blood-Testis Barrier | 1 | 2024 | 13 | 0.060 |
Why?
|
| Receptors, Eph Family | 1 | 2024 | 22 | 0.060 |
Why?
|
| Receptor, EphA2 | 1 | 2024 | 29 | 0.050 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2024 | 56 | 0.050 |
Why?
|
| Cytochrome P-450 CYP3A Inhibitors | 1 | 2023 | 11 | 0.050 |
Why?
|
| Carbon | 1 | 2024 | 98 | 0.050 |
Why?
|
| Bone Morphogenetic Protein Receptors, Type II | 1 | 2023 | 15 | 0.050 |
Why?
|
| Duloxetine Hydrochloride | 1 | 2022 | 14 | 0.050 |
Why?
|
| Oxidation-Reduction | 1 | 2024 | 468 | 0.050 |
Why?
|
| Central Nervous System Agents | 1 | 2022 | 16 | 0.050 |
Why?
|
| Cytochrome P-450 CYP2D6 | 1 | 2022 | 35 | 0.050 |
Why?
|
| Moon | 1 | 2022 | 13 | 0.050 |
Why?
|
| Cytochrome P-450 CYP1A2 | 1 | 2022 | 49 | 0.050 |
Why?
|
| Luciferases, Firefly | 1 | 2022 | 13 | 0.050 |
Why?
|
| Orphan Nuclear Receptors | 1 | 2022 | 21 | 0.050 |
Why?
|
| Cluster Analysis | 1 | 2023 | 440 | 0.050 |
Why?
|
| Propranolol | 1 | 2022 | 130 | 0.050 |
Why?
|
| Semen | 1 | 2022 | 80 | 0.050 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2022 | 109 | 0.050 |
Why?
|
| Glutathione | 1 | 2023 | 201 | 0.050 |
Why?
|
| Serotonin | 1 | 2022 | 226 | 0.050 |
Why?
|
| Quantitative Structure-Activity Relationship | 1 | 2021 | 15 | 0.040 |
Why?
|
| Protein Conformation, beta-Strand | 1 | 2021 | 15 | 0.040 |
Why?
|
| Protein Conformation, alpha-Helical | 1 | 2021 | 17 | 0.040 |
Why?
|
| Endometriosis | 1 | 2024 | 186 | 0.040 |
Why?
|
| Protein Domains | 1 | 2022 | 260 | 0.040 |
Why?
|
| RNA, Double-Stranded | 1 | 2021 | 67 | 0.040 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2021 | 149 | 0.040 |
Why?
|
| Molecular Docking Simulation | 1 | 2021 | 127 | 0.040 |
Why?
|
| A549 Cells | 1 | 2020 | 49 | 0.040 |
Why?
|
| Cell Movement | 1 | 2024 | 920 | 0.040 |
Why?
|
| Buffers | 1 | 2020 | 32 | 0.040 |
Why?
|
| Gene Amplification | 1 | 2021 | 247 | 0.040 |
Why?
|
| Adaptive Immunity | 1 | 2021 | 96 | 0.040 |
Why?
|
| Cytoplasm | 1 | 2021 | 304 | 0.040 |
Why?
|
| Introns | 1 | 2021 | 319 | 0.040 |
Why?
|
| Protein Engineering | 1 | 2019 | 74 | 0.040 |
Why?
|
| Cloning, Molecular | 1 | 2021 | 912 | 0.040 |
Why?
|
| RNA Splicing | 1 | 2021 | 252 | 0.040 |
Why?
|
| Transfection | 1 | 2020 | 1098 | 0.040 |
Why?
|
| Molecular Targeted Therapy | 1 | 2021 | 407 | 0.040 |
Why?
|
| RNA, Small Interfering | 1 | 2019 | 720 | 0.030 |
Why?
|
| Cognition | 1 | 2022 | 819 | 0.030 |
Why?
|
| Male | 4 | 2024 | 66171 | 0.030 |
Why?
|
| Gene Expression | 1 | 2021 | 1622 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2022 | 4012 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2022 | 2562 | 0.030 |
Why?
|
| Apoptosis | 1 | 2021 | 1945 | 0.030 |
Why?
|
| Transcriptional Activation | 1 | 2013 | 504 | 0.020 |
Why?
|
| Female | 3 | 2024 | 72002 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2010 | 158 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2013 | 1626 | 0.020 |
Why?
|
| Drug Delivery Systems | 1 | 2010 | 231 | 0.020 |
Why?
|